FindTrial
Sign In

A NEW TREATMENT FOR DHAT SYNDROME

EVALUATION OF THE EFFICACY OF NOVEL TREATMENT STRATEGY TO TREAT DHAT SYNDROME: A PILOT STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043531
Enrollment
30
Registered
2022-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F59- Unspecified behavioral syndromes associated with physiological disturbances and physical factors

Interventions

Intervention1: Reversible anejaculation induced by Silodosin 8 mg for 2 months: Reversible anejaculation induced by Silodosin 8 mg compared with Placebo Intervention2: Silodosin 8 mg: Silodosin 8 mg c

Sponsors

TSS Shripad Hegde Kadave Institute of Medical Sciences Sirsi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All males complaining of symptoms suggestive of dhat syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Change in the mental construct of the participant towards DHAT syndromeTimepoint: 1. At the beginning of the study 2. At the end of 8 weeks—

Secondary

MeasureTime frame
Adverse events due to SilodosinTimepoint: 8 weeks—

Countries

India

Contacts

Public ContactDr Gajanan Bhat

TSS Shripad Hegde Kadave Institute of Medical Sciences, Sirsi

gajubhatru@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026